142 related articles for article (PubMed ID: 23441851)
21. New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival.
Chabot C; Spring K; Gratton JP; Elchebly M; Royal I
Mol Cell Biol; 2009 Jan; 29(1):241-53. PubMed ID: 18936167
[TBL] [Abstract][Full Text] [Related]
22. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
[TBL] [Abstract][Full Text] [Related]
23. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization.
Dougher M; Terman BI
Oncogene; 1999 Feb; 18(8):1619-27. PubMed ID: 10102632
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of autophosphorylation of epidermal growth factor receptor by a small peptide not employing an ATP-competitive mechanism.
Abe M; Kuroda Y; Hirose M; Kato M; Murakami M; Watanabe Y; Nakano M; Handa T
Biopolymers; 2008 Jan; 89(1):40-51. PubMed ID: 17849478
[TBL] [Abstract][Full Text] [Related]
25. Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates.
Ward NE; O'Brian CA
Mol Pharmacol; 1992 Feb; 41(2):387-92. PubMed ID: 1538715
[TBL] [Abstract][Full Text] [Related]
26. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38.
Lamalice L; Houle F; Jourdan G; Huot J
Oncogene; 2004 Jan; 23(2):434-45. PubMed ID: 14724572
[TBL] [Abstract][Full Text] [Related]
29. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Itk tyrosine kinase: contribution of noncatalytic domains to enzymatic activity.
Hawkins J; Marcy A
Protein Expr Purif; 2001 Jul; 22(2):211-9. PubMed ID: 11437596
[TBL] [Abstract][Full Text] [Related]
31. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
[TBL] [Abstract][Full Text] [Related]
32. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.
McTigue MA; Wickersham JA; Pinko C; Showalter RE; Parast CV; Tempczyk-Russell A; Gehring MR; Mroczkowski B; Kan CC; Villafranca JE; Appelt K
Structure; 1999 Mar; 7(3):319-30. PubMed ID: 10368301
[TBL] [Abstract][Full Text] [Related]
33. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
34. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
[TBL] [Abstract][Full Text] [Related]
35. Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.
Liu C; Guo L; Yao C; Zhang R; Li Y
Biotechnol Appl Biochem; 2008 Jun; 50(Pt 2):113-9. PubMed ID: 17824843
[TBL] [Abstract][Full Text] [Related]
36. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
Kiselyov AS; Semenov VV; Milligan D
Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
[TBL] [Abstract][Full Text] [Related]
37. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
[TBL] [Abstract][Full Text] [Related]
38. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
[TBL] [Abstract][Full Text] [Related]
39. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
40. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
